0001209191-23-007396.txt : 20230206 0001209191-23-007396.hdr.sgml : 20230206 20230206211221 ACCESSION NUMBER: 0001209191-23-007396 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230202 FILED AS OF DATE: 20230206 DATE AS OF CHANGE: 20230206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Alam Kamran CENTRAL INDEX KEY: 0001793412 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 23592514 MAIL ADDRESS: STREET 1: 350 FIFTH AVENUE, SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-02 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001793412 Alam Kamran C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, STE 1430 DALLAS TX 75247 0 1 0 0 Chief Financial Officer Common Stock 2023-02-02 4 A 0 18691 A 284812 D Employee Stock Option (right to buy) 1.18 2023-02-02 4 A 0 37384 0.00 A 2033-02-02 Common Stock 37384 37384 D Employee Stock Option (right to buy) 1.18 2023-02-02 4 A 0 149900 0.00 A 2033-02-02 Common Stock 149900 149900 D Represents a restricted stock unit ("RSU") award. 12,461 RSUs shall vest 25% on each of February 2, 2024, February 2, 2025, February 2, 2026 and February 2, 2027. The remaining RSUs, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. Each RSU represents a contingent right to receive one share the Issuer's common stock. 24,923 shares underlying the option shall vest 25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter. The remaining shares underlying the option, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. 25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam 2023-02-06